文献

J-GLOBAL ID：202202239824177674   整理番号：22A0567899

二価ナノ粒子ワクチンはSARS-CoV-2の変異体に対して強力な交差防御を示す【JST・京大機械翻訳】

A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2

著者 (29件)： Yuan Yaochang (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Zhang Xiantao (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Chen Ran (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Li Yuzhuang (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Wu Bolin (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Li Rong (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Zou Fan (Qianyang Biomedical Research Institute, Guangzhou, Guangdong 510063, China) ,  Ma Xiancai (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Wang Xuemei (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Chen Qier (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Deng Jieyi (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Zhang Yongli (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Chen Tao (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Lin Yingtong (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Yan Shumei (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Yan Shumei (Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong 510060, China) ,  Zhang Xu (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Li Congrong (BSL-3 Laboratory, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China) ,  Bu Xiuqing (BSL-3 Laboratory, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China) ,  Peng Yi (BSL-3 Laboratory, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China) ,  Ke Changwen (Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong 511430, China) ,  Deng Kai (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Deng Kai (BSL-3 Laboratory, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China) ,  Deng Kai (Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China) ,  Pan Ting (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  He Xin (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Zhang Yiwen (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Zhang Hui (Institute of Human Virology, Key Laboratory of Tropical Disease Control of the Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agents and Immunotechnology, Engineering Research Center of Gene Vaccine of the Ministry of Education, Zhongshan School of Medicine...) ,  Zhang Hui (National Guangzhou Laboratory, Bio-Island, Guangzhou, Guangdong 510320, China)
資料名： Cell Reports  (Cell Reports)
巻： 38  号： 3  ページ： Null  発行年： 2022年 
JST資料番号： W3124A  ISSN： 2211-1247  資料種別： 逐次刊行物 (A)
記事区分： 短報  発行国： オランダ (NLD)  言語： 英語 (EN)

抄録/ポイント： 重症急性呼吸器症候群コロナウイルス2(SARS-CoV-2)に対する接種は世界中で進行中である。しかし,SARS-CoV-2変異体の出現は,免疫回避を引き起こす可能性がある。D614GとB.1.351株の受容体結合ドメイン(RBD)を示す二価ナノ粒子ワクチンを開発した。プライムブーストまたは単回投与戦略により,このワクチンは,ヒトアンギオテンシン変換酵素2導入遺伝子マウスにおいて,真正D614GまたはB.1.351株による感染に対して,頑健な中和抗体および完全な防御を誘発する。興味深いことに,D614G特異的ワクチンによる接種8か月後,この二価ワクチンによる新規ブーストはアカゲザルにおけるSARS-CoV-2変異体に対する交差中和抗体を強力に誘発する。著者らは,D614G/B.1.351二価ワクチンが,SARS-CoV-2とその変異体による感染を予防するための初期単回投与または逐次施行用量として使用できることを示唆する。Copyright 2022 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： 受容体 ,  *突然変異体 ,  ヒト ,  マウス ,  免疫反応 ,  *ワクチン ,  結合部位 ,  アカゲザル ,  単回投与 ,  中和抗体 ,  *ナノ粒子
準シソーラス用語： *重症急性呼吸器症候群 ,  導入遺伝子 ,  アンギオテンシン変換酵素2 ,  免疫回避 , 【Automatic Indexing@JST】

著者キーワード (3件)： SARS-CoV-2変異体 ,  B.1.351変異体 ,  二価ナノ粒子ワクチン

分類 (1件)： 免疫療法薬・血液製剤の基礎研究  (GW22010D)

タイトルに関連する用語 (4件)： ナノ粒子ワクチン ,  SARS-CoV-2 ,  変異体 ,  交差防御